Alphacalcidol and renal function in normal subjects.
Sixteen young healthy adults were treated for 3 weeks with alphacalcidol (1 alpha OHD3), 1 microgram orally per day, and renal function tests were performed before, at the end and 3 weeks after termination of the drug. No significant changes occurred in the serum concentrations of calcium or phosphate, whereas the serum calcium-phosphorus product and the urinary excretion of calcium increased significantly. Serum creatinine and the urinary excretion of creatinine showed no significant changes. Inulin clearance decreased by 4% (p = 0.11). The total plasma clearance rate of 51Cr-EDTA and the 24-hour endogenous creatinine clearance both decreased by 4% during the treatment (p less than 0.05). It is concluded that treatment of normal subjects with 1 alpha OHD3, in a modest dose causing no significant change in serum calcium, is associated with a small but reversible decrease in renal function.
Tvedegaard
E
E
Medical Department P, Rigshospitalet, Copenhagen, Denmark.
Madsen
S
S
D000328:Adult; D003404:Creatinine / Q000378:metabolism; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006887:Hydroxycholecalciferols / Q000633:toxicity*; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008297:Male
D006887:Hydroxycholecalciferols; D003404:Creatinine; C008088:alfacalcidol